Hyperuricemia
Conditions
Interventions
Febuxostat 10mg once a day for 2 weeks. Febuxostat 20mg once a day after 2 weeks
Sponsors
St. Lukes International Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: hyperuricemia patients eligible for all the points of the following: (1) Japanese male or female, 20 years old or above at the time of informed consent (2) Serum uric acid > 8.0mg/dL (3) Not treated with uric acid lowering agent within 3 month before the timing of eligibility judgement (4) Patients enable to measure vascular endotherial function (5) Patinets from which informed consent is obtained
Exclusion criteria
Exclusion criteria: (1)Patients having anti-hyperuricemia medication (2)Patients with hypersensitivity to febuxostat (3)HbA1c is 8% and over (4)Patients with medication including NO donor (5)Hepatic impairment patients (AST, ALT is more than double of standard values) (6)Pregnant female, lactation femal, hoping gestation (7)Patients with corticosteroid 10mg/day and over (8)Treated patients with mercaptopurine or azathioprine (9)Patints having malignancy (10)Patients whom study physicians consider as not eligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Vascular endothelial function(flow mediated dilatation, pulse wave velocity, carotid intima-media thickness) 2. Cardio-renal function(NT-pro BNP, estimated GFR, cardiac echography) 3. Blood pressure | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The change of serum uric acid 2. Ankle brachial index 3. Cytokine: 9-OhdG, MDA-LDL, CRP, IL-6, AGE, RAGE, NOx, Angintensin2, ADMA, IGF-alpha 4. Blood sugar, insulin, HbA1c, HOMA-beta 5. LDL-cholesterol, HDL-cholesterol, trigliceride 6. Blood test: BUN, creatinine, AST, ALT, LDH, ALP, sodium, potacium, cloride, homocystein 7. Urine test: uric acid, creatinin, sodium, potacium, cloride | — |
Countries
Japan
Contacts
Public ContactKuwabara Masanari
St. Lukes International Hospital Department of Cardiology
Outcome results
None listed